Alert detail
FDA Approval: EYDENZELT (AFLIBERCEPT-BOAV) — Type 3 - New Dosage Form
Policy ID: FDA-BLA761377Specialty: OphthalmologyAdded: 10/2/2026Effective: October 2, 2025billing update
What changed
Aflibercept biosimilar approved; watch for new Q-code assignment.
Who’s affected: Ophthalmology billing teams · Effective: October 2, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.